{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:14:50Z","timestamp":1793999690134,"version":"4.8.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.1001\/jamaoncol.2021.4664","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T17:59:41Z","timestamp":1634579981000},"page":"1772","source":"Crossref","is-referenced-by-count":73,"title":["Preexisting <i>TP53<\/i>-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib"],"prefix":"10.1001","volume":"7","author":[{"given":"Tanya T.","family":"Kwan","sequence":"first","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[{"name":"BC Cancer\u2013Vancouver, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour les Etudes des Cancers de l\u2019Ovaire, Lyon, France"},{"name":"Medical Oncology Department, Centre L\u00e9on B\u00e9rard, Lyon, France"},{"name":"Centre L\u00e9on B\u00e9rard, University Claude Bernard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Now with Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Gynecologic Cancer Medical Treatments, European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Obstetrics and Gynaecology, University of Milan-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dean","sequence":"additional","affiliation":[{"name":"Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Weberpals","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Severson","sequence":"additional","affiliation":[{"name":"Pathology and Diagnostic Medicine, Foundation Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Thanh","family":"Vo","sequence":"additional","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Goble","sequence":"additional","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Maloney","sequence":"additional","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harding","sequence":"additional","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[{"name":"Department of Oncology, UCL Cancer Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, The University of Texas, Houston"},{"name":"Now with US Oncology Research, The Woodlands, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"McNeish","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Lin","sequence":"additional","affiliation":[{"name":"Clovis Oncology Inc, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi210068r1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide.","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"coi210068r2","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.2147\/OTT","article-title":"Therapy-related myeloid neoplasms: clinical perspectives.","volume":"11","author":"Fianchi","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"5","key":"coi210068r3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer.","volume":"340","author":"Travis","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"coi210068r4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era.","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"coi210068r5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"coi210068r6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"coi210068r7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.","volume":"8","author":"Ok","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"coi210068r8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/asheducation-2018.1.264","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential.","volume":"2018","author":"Steensma","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6465","key":"coi210068r9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease.","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"26","key":"coi210068r10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"coi210068r11","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"coi210068r12","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"coi210068r13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes.","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"1","key":"coi210068r14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi210068r15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","article-title":"Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma.","volume":"2","author":"Swisher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"coi210068r16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis.","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"1","key":"coi210068r17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi210068r19","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"coi210068r20","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2020.38.15_suppl.3601","article-title":"Myelodysplastic syndrome and acute myeloid leukemia as side effect of PARP inhibitors.","volume":"38","author":"Master","year":"2020","journal-title":"J Clin Oncol"},{"key":"coi210068r21","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1200\/JCO.2018.36.15_suppl.5548","article-title":"Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: impact of prior lines of platinum therapy.","volume":"36","author":"Korach","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210068r22","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"coi210068r23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"coi210068r24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"7540","key":"coi210068r25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"coi210068r18","year":"2020"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2784883\/jamaoncology_kwan_2021_oi_210068_1639155133.60799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:23:15Z","timestamp":1639671795000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2784883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.4664","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}